Sonova's Premium Valuation More Challenging Given Growth Trends And Macro Pressures

2025-03-11 09:19:35 ET

Summary

• Fiscal first-half results were underwhelming, with revenue and EBITA growth below expectations, and growing macro pressures could hit 2025 growth and margin estimates.
• Hearing aid sales, particularly in the U.S., are economically-sensitive and weaker consumer confidence could lead to slower market growth.
• Management has indicated that the U.S. government is reexamining VA contracts, and this is a major channel for the company's U.S. business.
• Despite strong R&D and market leadership, Sonova shares appear fairly valued; were reduced expectations to drive a pullback, that could be an opportunity to buy the dip.

These are more challenging days for medical device companies that rely more on consumer out-of-pocket spending, to say nothing of those that also have significant exposure to agencies of the U.S. government. That’s the case today with Sonova (SONVVY) ( OTCPK:SONVF ) (SOON.SW), though, and I’m concerned about the combination of high valuation, “ordinary” growth prospects, and potential macro pressures in 2025....

Read the full article on Seeking Alpha

For further details see: